Prevest Denpro Adjusts Evaluation Amid Record Sales and Changing Market Trends

Prevest Denpro, a microcap company in the healthcare services sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the technical trends associated with the stock, moving from a sideways trajectory to a mildly bearish outlook.
In terms of key financial metrics, Prevest Denpro reported a notable performance in its latest quarter, achieving record net sales of Rs 18.45 crore and a PBDIT of Rs 6.54 crore. The company has demonstrated a solid return on equity of 17.2%, although its long-term growth has been characterized by a modest annual increase in net sales of 12.47% and operating profit of 3.25% over the past five years.

The stock is currently trading at a price-to-book value of 5.5, indicating a valuation that is considered expensive relative to its peers. Despite a year-on-year return of 11.93%, the company's profits have only risen by 12.9%, resulting in a PEG ratio of 2.3. Additionally, the company maintains a low debt-to-equity ratio, which stands at 0 times.

Institutional investors have shown increasing participation, raising their stake by 0.57% in the previous quarter, now holding 1.91% of the company.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.